Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implicationsmarketing2021-02-11T23:40:44+00:00October 15th, 2019|2019 Publications, Publications| 続きを読む
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myelomamarketing2021-02-11T23:43:09+00:00October 1st, 2019|2019 Publications, Publications| 続きを読む
NOW AVAILABLE! MRD solutions for B- and T-cell clonality trackingmarketing2019-09-23T22:05:58+00:00August 26th, 2019|Product Releases| 続きを読む
日本の厚生労働省は、インビボスクライブの リューコストラット CDx FLT3変異検査を、再発/難治性で FLT3-ITD陽性の急性骨髄性白血病の治療に第一三共株式会社製キザルチニブを投与する際ののコンパニオン診断薬として承認しました。また、検体のEDTAでの採取保存にも適用を拡大します。marketing2021-12-29T23:23:13+00:00June 19th, 2019|2019 プレスリリース, プレスリリース| 続きを読む
Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myelomamarketing2021-02-15T20:01:10+00:00June 6th, 2019|2019 Publications, Publications| 続きを読む
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignanciesmarketing2021-02-26T19:10:45+00:00May 21st, 2019|2019 プレスリリース, プレスリリース| 続きを読む
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasmsmarketing2021-02-11T23:46:14+00:00March 21st, 2019|2019 Publications, Featured Publications, Publications| 続きを読む
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in Japanmarketing2021-02-26T19:11:02+00:00November 29th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinibmarketing2021-02-26T19:11:39+00:00November 19th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japanmarketing2021-02-26T19:11:48+00:00November 19th, 2018|2018 プレスリリース, プレスリリース| 続きを読む
